ATE326233T1 - Langfristig stabilisierte g-csf präparate - Google Patents

Langfristig stabilisierte g-csf präparate

Info

Publication number
ATE326233T1
ATE326233T1 AT00905397T AT00905397T ATE326233T1 AT E326233 T1 ATE326233 T1 AT E326233T1 AT 00905397 T AT00905397 T AT 00905397T AT 00905397 T AT00905397 T AT 00905397T AT E326233 T1 ATE326233 T1 AT E326233T1
Authority
AT
Austria
Prior art keywords
csf
long
residual ratio
testing
accelerated testing
Prior art date
Application number
AT00905397T
Other languages
English (en)
Inventor
Yasushi Sato
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE326233T1 publication Critical patent/ATE326233T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Amplifiers (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Fodder In General (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT00905397T 1999-03-01 2000-02-29 Langfristig stabilisierte g-csf präparate ATE326233T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11052314A JP2000247903A (ja) 1999-03-01 1999-03-01 長期安定化製剤

Publications (1)

Publication Number Publication Date
ATE326233T1 true ATE326233T1 (de) 2006-06-15

Family

ID=12911333

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00905397T ATE326233T1 (de) 1999-03-01 2000-02-29 Langfristig stabilisierte g-csf präparate

Country Status (16)

Country Link
US (1) US6908610B1 (de)
EP (2) EP1700605B1 (de)
JP (2) JP2000247903A (de)
KR (2) KR100731559B1 (de)
CN (3) CN1342087A (de)
AT (1) ATE326233T1 (de)
AU (1) AU772604B2 (de)
CA (1) CA2381229C (de)
CY (1) CY1105528T1 (de)
DE (1) DE60028037T2 (de)
DK (1) DK1197221T3 (de)
ES (1) ES2263450T3 (de)
HK (2) HK1046239B (de)
PT (1) PT1197221E (de)
TW (1) TWI232749B (de)
WO (1) WO2000051629A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100709792B1 (ko) * 1999-12-24 2007-04-19 오츠카 세이야쿠 가부시키가이샤 소수성 아미노산을 포함하는 건조 조성물
US7163671B2 (en) 2000-02-29 2007-01-16 Chugai Seiyaku Kabushiki Kaisha Long-term stabilized formulations
DE60109625T3 (de) * 2000-05-15 2017-08-03 F. Hoffmann-La Roche Ag Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
EP1930024A3 (de) * 2000-09-01 2008-08-06 Chugai Seiyaku Kabushiki Kaisha G-CSF Lösungsformulierung mit Langzeitstabilität
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
CA2423227C (en) 2000-10-12 2011-11-29 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
WO2003055512A1 (en) 2001-12-21 2003-07-10 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
WO2003072123A1 (fr) * 2002-02-28 2003-09-04 Nipro Corporation Preparations d'albumine stabilisees
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
PL207018B1 (pl) 2002-06-21 2010-10-29 Novo Nordisk Helth Care Ag Kompozycja farmaceutyczna, sposób przygotowania stabilnego polipeptydu czynnika VII i zastosowanie polipeptydu czynnika VII
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
EP1541165A4 (de) * 2002-08-27 2009-06-24 Chugai Pharmaceutical Co Ltd Verfahren zur stabilisierung einer proteinl sungszubereitung
AU2004216298B2 (en) * 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
AU2004222625A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
SI2335725T1 (sl) * 2003-04-04 2017-01-31 Genentech, Inc. Visokokoncentrirane formulacije protiteles in proteinov
ATE454900T1 (de) * 2003-05-23 2010-01-15 Novo Nordisk Healthcare Ag Stabilisierung von proteinen in lösung
ES2335994T3 (es) * 2003-07-01 2010-04-07 Novo Nordisk Health Care Ag Composicion farmaceutica liquida, acuosa de polipeptidos factor vii.
FR2857267B1 (fr) * 2003-07-09 2006-03-10 Lab Francais Du Fractionnement Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
KR20120104619A (ko) * 2003-08-14 2012-09-21 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
AU2004288854B2 (en) * 2003-11-10 2009-10-01 Arriva-Pharmaceuticals, Inc. Dry recombinant human alpha 1-antitrypsin formulation
ES2375706T3 (es) * 2003-11-14 2012-03-05 Baxter International Inc. Composiciones de alfa 1-antitripsina y métodos de tratamiento que usan tales composiciones.
CN1917861B (zh) * 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
DE202004020676U1 (de) * 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
JP2005310840A (ja) 2004-04-16 2005-11-04 Toshiba Corp 磁気ランダムアクセスメモリ
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US20060293243A1 (en) * 2005-06-17 2006-12-28 Navneet Puri Stable, buffered, pharmaceutical compositions including motilin-like peptides
US7534753B2 (en) * 2006-01-12 2009-05-19 Air Products And Chemicals, Inc. pH buffered aqueous cleaning composition and method for removing photoresist residue
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
WO2007108505A1 (ja) * 2006-03-22 2007-09-27 Chugai Seiyaku Kabushiki Kaisha エリスロポエチン溶液製剤
US9119789B2 (en) 2007-04-05 2015-09-01 Sandoz Ag Stable aqueous G-CSF formulations
US20080286471A1 (en) * 2007-05-18 2008-11-20 Doubleday Marc D Protective gel for an electrical connection
MX2009013886A (es) * 2007-06-25 2010-01-27 Amgen Inc Composiciones de agentes de aglutinacion especifica al factor de crecimiento de los hepatocitos.
BRPI0813948B8 (pt) 2007-07-10 2021-05-25 Medy Tox Inc composição líquida farmacêutica de toxina botulínica com estabilidade melhorada
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
KR20100111682A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
EP2334323A2 (de) * 2008-09-10 2011-06-22 F. Hoffmann-La Roche AG Zusammensetzungen und verfahren zur prävention des oxidativen abbaus von proteinen
LT3228320T (lt) 2008-10-17 2020-03-10 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
PE20120359A1 (es) 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
KR101772372B1 (ko) 2009-11-13 2017-08-29 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
PE20121362A1 (es) 2009-11-13 2012-10-17 Sanofi Aventis Deutschland Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
EA031209B9 (ru) * 2010-01-15 2021-11-19 Кирин-Эмджен, Инк. Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
TWI609698B (zh) * 2010-01-20 2018-01-01 中外製藥股份有限公司 穩定化的含抗體溶液製劑
ES2765418T3 (es) 2010-03-01 2020-06-09 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
EP2399572A1 (de) 2010-06-22 2011-12-28 Sandoz AG Langzeitaufbewahrung von nicht-glykosyliertem rekombinantem humanem G-CSF
EP2611458B1 (de) 2010-08-30 2016-09-21 Sanofi-Aventis Deutschland GmbH Verwendung von ave0010 für die herstellung eines medikaments zur behandlung von diabetes mellitus typ 2
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CN102028661B (zh) * 2010-12-31 2012-05-23 山东新时代药业有限公司 聚乙二醇化重组人粒细胞集落刺激因子冻干粉针剂及其制备方法
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AU2012300978B2 (en) 2011-08-29 2017-04-27 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013142336A1 (en) * 2012-03-21 2013-09-26 Miller Leonard B Combination therapy to improve joint, tendon, and ligament healing
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
CA2905588C (en) 2013-03-12 2018-11-06 Sumitomo Dainippon Pharma Co., Ltd. Liquid aqueous composition
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
CA3113172A1 (en) * 2013-03-13 2014-10-02 Genentech, Inc. Screen for compound that prevents protein oxidation based on comparison with l-tryptophan
RS60534B1 (sr) * 2013-03-13 2020-08-31 Hoffmann La Roche Formulacije sa smanjenom oksidacijom
WO2015076285A1 (ja) * 2013-11-21 2015-05-28 協和メデックス株式会社 血清又は血漿中の低密度リポ蛋白の凍結乾燥による変性抑制剤及び変性抑制方法
AU2015205624A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9895423B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
RU2016132386A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы без глицерина на основе инсулиновых аналогов и/или инсулиновых производных
CN104524553B (zh) * 2014-12-12 2015-07-29 薛传校 一种长效促排卵注射液
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
CN109627300B (zh) * 2019-02-18 2022-08-05 浙江新银象生物工程有限公司 Nisin溶液稳定剂开发及应用
EP4110370A4 (de) * 2020-03-30 2023-06-07 Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. Formulierungen des humanen parathyroidhormons (pth) und verfahren zur herstellung davon
WO2023066988A1 (en) 2021-10-19 2023-04-27 Sandoz Ag Glass container with low aluminum content and gas overlay to prevent oxidation of sensitive therapeutic agents
CN115624187B (zh) * 2022-12-08 2023-04-04 北京第一生物科技开发有限公司 牛脾肽粉在改善睡眠中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
JP2577744B2 (ja) * 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
DE3729863A1 (de) 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JP2974722B2 (ja) 1990-04-03 1999-11-10 帝国臓器製薬株式会社 カルシトニン注射液
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
GB9120304D0 (en) * 1991-09-24 1991-11-06 Erba Carlo Spa Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor
US5192743A (en) 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
JPH05331071A (ja) * 1992-01-17 1993-12-14 Asahi Chem Ind Co Ltd カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法
IL107887A (en) 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5780431A (en) * 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
HUP0203133A3 (en) * 1999-10-04 2005-07-28 Chiron Corp Emeryville Stabilized liquid polypeptide-containing pharmaceutical compositions

Also Published As

Publication number Publication date
CN1342087A (zh) 2002-03-27
KR100656125B1 (ko) 2006-12-12
KR20010102469A (ko) 2001-11-15
DE60028037D1 (de) 2006-06-22
PT1197221E (pt) 2006-08-31
EP1197221A4 (de) 2003-01-29
CY1105528T1 (el) 2010-07-28
EP1197221A1 (de) 2002-04-17
EP1700605A3 (de) 2007-06-13
CA2381229A1 (en) 2000-09-08
JP4607336B2 (ja) 2011-01-05
TWI232749B (en) 2005-05-21
US6908610B1 (en) 2005-06-21
AU2695400A (en) 2000-09-21
HK1098963A1 (zh) 2007-08-03
CA2381229C (en) 2010-10-26
KR20050099637A (ko) 2005-10-14
CN1879875A (zh) 2006-12-20
WO2000051629A1 (en) 2000-09-08
DK1197221T3 (da) 2006-11-13
AU772604B2 (en) 2004-05-06
CN101537173A (zh) 2009-09-23
EP1197221B1 (de) 2006-05-17
JP2000247903A (ja) 2000-09-12
DE60028037T2 (de) 2006-12-21
HK1045652A1 (zh) 2002-12-06
KR100731559B1 (ko) 2007-06-22
HK1046239A1 (en) 2003-01-03
ES2263450T3 (es) 2006-12-16
EP1700605A2 (de) 2006-09-13
EP1700605B1 (de) 2014-04-30
HK1046239B (en) 2006-08-18
CN1879875B (zh) 2010-08-25

Similar Documents

Publication Publication Date Title
ATE326233T1 (de) Langfristig stabilisierte g-csf präparate
NO883926D0 (no) Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat.
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
DK2016950T3 (da) Farmaceutisk sammensætning omfattende et exendin-4-peptid
HUP0000589A2 (hu) Vizes peptid készítmények
GB2341801B (en) Formulation
NO965012L (no) Farmasöytisk preparat som omfatter glukagon
DE69508837D1 (de) Protein enthaltende stabilisierte Formulierung und Dosierungskit
DK395689D0 (da) Pharmaceutisk tilberedning til behandling af diabetes mellitus
DK0588539T3 (da) Stabiliserede farmaceutiske præparater indeholdende derivater af vitamin D2 og D3
TR199802534T2 (xx) Leptin (OB Protein) fragmanlar�
BR9908088A (pt) Formulação farmacêutica de um composto de didemnin
PT785795E (pt) Composicao farmaceutica
MX9203175A (es) Composicion de implante que contiene un peptido, polipeptido o proteina biologicamente activa y procedimiento para su preparacion.
ES2055607T3 (es) Composiciones farmaceuticas estables que contienen un factor de crecimiento de fibroblastos.
HRP20020071B1 (hr) Farmaceutske kompozicije i pripravljanje istih
WO2004032863A3 (en) Oral formulations for proteins and polypeptides
SE9904132D0 (sv) Pharmaceutical composition for treatment of diarrhea
EA200400954A1 (ru) Фармацевтическая композиция, содержащая 2,2-дихлор-12-(4-хлорфенил)додекановую кислоту
IT1241459B (it) Composizioni farmaceutiche per la somministrazione rettale di calcitonina
MX9800309A (es) Formulacion farmaceutica estabilizada que comprende una hormona del crecimiento y un peptido que comprende al menos un residuo de aminoacido basico y al menos un residuo de aminoacido acido.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1197221

Country of ref document: EP